The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy.

@article{Julius2006TheVA,
  title={The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy.},
  author={Stevo Julius and Michael D Weber and Sverre Erik Kjeldsen and Gordon T. McInnes and Alberto Zanchetti and Hans Rudolf Brunner and John H. Laragh and M. Anthony Schork and Tsushung Augie Hua and John V. Amerena and Ivan Balazovjech and Graham Cassel and Bela Herczeg and Nevres Koylan and Dieter Magometschnigg and Silja K Majahalme and Felipe Martinez and Willie Oigman and Ricardo Seabra Gomes and Jun-ren Zhu},
  journal={Hypertension},
  year={2006},
  volume={48 3},
  pages={385-91}
}
In the main Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) report, we investigated outcomes in 15 245 high-risk hypertensive subjects treated with valsartan- or amlodipine-based regimens. In this report, we analyzed outcomes in 7080 patients (46.4%) who, at the end of the initial drug adjustment period (6 months), remained on monotherapy. Baseline characteristics were similar in the valsartan (N=3263) and amlodipine (N=3817) groups. Time on monotherapy was 3.2 years (78% of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 58 extracted citations

Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome.

Journal of the American Society of Hypertension : JASH • 2008
View 5 Excerpts
Highly Influenced

Gene therapy for hypertension.

Expert opinion on biological therapy • 2017
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 17 references

The cardiovascular continuum and renin-angiotensin-aldosterone system blockade.

Journal of hypertension. Supplement : official journal of the International Society of Hypertension • 2005

Similar Papers

Loading similar papers…